Assignee
ALS THERAPY DEVELOPMENT INST
US·14 granted patents·4 pending applications·36 citations·filing 2017–2025
Top patents by PatentIndex Score
18 records- 0195US11692040B2Anti-CD40L antibodies and methods for treating CD40L-related diseases or disordersALS THERAPY DEVELOPMENT INST·Filed 2021·Granted Jul 4, 2023·4 cites·8 claims
- 0295US11014990B2Anti-CD40L antibodiesALS THERAPY DEVELOPMENT INST·Filed 2020·Granted May 25, 2021·6 cites·10 claims
- 0393US10683356B2Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodiesALS THERAPY DEVELOPMENT INST·Filed 2018·Granted Jun 16, 2020·8 cites·4 claims
- 0490US10106618B2Anti-CD40L antibodiesALS THERAPY DEVELOPMENT INST·Filed 2017·Granted Oct 23, 2018·8 cites·9 claims
- 0587US11384152B2Therapeutic anti-CD40 ligand antibodiesALS THERAPY DEVELOPMENT INST·Filed 2018·Granted Jul 12, 2022·6 cites·10 claims
- 0686US11857534B2Inhibition of dipeptide repeat proteinsALS THERAPY DEVELOPMENT INST·Filed 2022·Granted Jan 2, 2024·1 cites·24 claims
- 0785US12275793B2Anti-CD40L antibodies and methods for treating CD40L-related diseases or disordersALS THERAPY DEVELOPMENT INST·Filed 2023·Granted Apr 15, 2025·0 cites·11 claims
- 0885US11607402B2Inhibition of dipeptide repeat proteinsALS THERAPY DEVELOPMENT INST·Filed 2020·Granted Mar 21, 2023·2 cites·6 claims
- 0978US12318365B2Inhibition of dipeptide repeat proteinsALS THERAPY DEVELOPMENT INST·Filed 2023·Granted Jun 3, 2025·0 cites·22 claims
- 1078US11708349B2Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditionsALS THERAPY DEVELOPMENT INST·Filed 2019·Granted Jul 25, 2023·1 cites·13 claims
- 1177US12157728B2Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditionsALS THERAPY DEVELOPMENT INST·Filed 2023·Granted Dec 3, 2024·0 cites·15 claims
- 1275US2025263493A1Anti-cd40l antibodies and methods for treating cd40l-related diseases or disordersALS THERAPY DEVELOPMENT INST·Filed 2025·Application pending·0 cites
- 1374US2026007635A1Inhibition of dipeptide repeat proteinsALS THERAPY DEVELOPMENT INST·Filed 2025·Application pending·0 cites
- 1473US12522618B2Copper complexes for treatment of neurodegenerative disordersALS THERAPY DEVELOPMENT INST·Filed 2024·Granted Jan 13, 2026·0 cites·20 claims
- 1567US2023048260A1Therapeutic anti-cd40 ligand antibodiesALS THERAPY DEVELOPMENT INST·Filed 2022·Application pending·0 cites
- 1666US2024016879A1Copper complexes for treatment of neurodegenerative disordersALS THERAPY DEVELOPMENT INST·Filed 2023·Application pending·0 cites
- 1765US12012422B2Copper complexes for treatment of neurodegenerative disordersALS THERAPY DEVELOPMENT INST·Filed 2021·Granted Jun 18, 2024·0 cites·14 claims
- 1861US11660324B2Copper complexes for treatment of neurodegenerative disordersALS THERAPY DEVELOPMENT INST·Filed 2020·Granted May 30, 2023·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when ALS THERAPY DEVELOPMENT INST files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →